Navigation Links
A study by the MUHC and McGill University opens a new door to understanding cancer
Date:8/13/2007

Montreal, 9 August 2007 - An in-depth understanding of the mechanisms that trigger cancer cell growth is vital to the development of more targeted treatments for the disease. An article published in the August 3 issue of Molecular Cell provides a key to these mechanisms that may prove crucial in the future. The paper is co-authored by Dr Morag Park, Director of the MUHC Molecular Oncology Group, and Dr Kalle Gehring, Head of the Nuclear Magnetic Resonnance Laboratory of the McGill University Biochemistry Department.

To understand cancer, it is necessary to first understand how the molecules interact, explains Dr. Park, who is also a Professor of oncology and biochemistry at McGill University. In that study we have clarified the structure of some of the proteins involved and their connections, which allows us to understand the consequences of these interactions. This is, in fact, a feat that merits close attention, because it means that researchers can now see elements smaller than a millionth of a millimetre!

In a cells interior, the function of the ubiquitin molecule is to clean house. It attaches itself to proteins that must disappear and triggers their degradation; in doing so, it allows a number of mechanisms to be minutely controlled. This new study reveals that ubiquitin also promotes interactions between proteins known as Cb-b. In a healthy patient, Cb-b is activated when a growth factor attaches itself to the surface of a cell, its role being to mitigate the cell proliferation and growth mechanisms induced by the factor. However, in some cancer patients this mitigation mechanism does not appear to function, partly because the ubiquitin does not attach itself correctly to the cell surface and to Cb-b. As a result, the effects of the growth factor become much more pronounced, which results in an unrestrained proliferation of cells that can become a cancer.

In the long term, this may serve as a basis for us to find ways to intervene in this chain reaction and discover a treatment adds Dr. Gehring. This new information about ubiquitin marks an important advance in our understanding of the mechanisms associated with cancer and contributes to the fight against the disease by directing us towards research avenues for new medications.


'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-934-1934
McGill University Health Centre
Source:Eurekalert

Related biology news :

1. Bioartificial kidney under study at MCG
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. W.M. Keck Foundation funds study of friendly microbes
4. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
5. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
6. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
7. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
8. Study Links Ebola Outbreaks To Animal Carcasses
9. Genome-wide mouse study yields link to human leukemia
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: